| Literature DB >> 34194925 |
David Panáček1,2, Lucie Hochvaldová2,3, Aristides Bakandritsos3,4, Tomáš Malina2,3, Michal Langer1,2, Jan Belza2,3, Jana Martincová2,3, Renata Večeřová5, Petr Lazar3, Kateřina Poláková1, Jan Kolařík3, Lucie Válková3, Milan Kolář5, Michal Otyepka1,3, Aleš Panáček2,3, Radek Zbořil1,4.
Abstract
The ability of bacteria to develop resistance to antibiotics is threatening one of the pillars of modern medicine. It was recently understood that bacteria can develop resistance even to silver nanoparticles by starting to produce flagellin, a protein which induces their aggregation and deactivation. This study shows that silver covalently bound to cyanographene (GCN/Ag) kills silver-nanoparticle-resistant bacteria at concentrations 30 times lower than silver nanoparticles, a challenge which has been so far unmet. Tested also against multidrug resistant strains, the antibacterial activity of GCN/Ag is systematically found as potent as that of free ionic silver or 10 nm colloidal silver nanoparticles. Owing to the strong and multiple dative bonds between the nitrile groups of cyanographene and silver, as theory and experiments confirm, there is marginal silver ion leaching, even after six months of storage, and thus very high cytocompatibility to human cells. Molecular dynamics simulations suggest strong interaction of GCN/Ag with the bacterial membrane, and as corroborated by experiments, the antibacterial activity does not rely on the release of silver nanoparticles or ions. Endowed with these properties, GCN/Ag shows that rigid supports selectively and densely functionalized with potent silver-binding ligands, such as cyanographene, may open new avenues against microbial resistance.Entities:
Keywords: antimicrobial; cytocompatibility; graphene; silver resistant
Mesh:
Substances:
Year: 2021 PMID: 34194925 PMCID: PMC8224420 DOI: 10.1002/advs.202003090
Source DB: PubMed Journal: Adv Sci (Weinh) ISSN: 2198-3844 Impact factor: 16.806
Figure 1a) Reaction scheme for the preparation of silver nanoparticles bonded on the nitrile groups of cyanographene (GCN/Ag). b) HAADF‐STEM image (and TEM image, inset) of a GCN flake after interaction with AgNO3. EDS chemical mapping of c) nitrogen and d) silver. e) Combined chemical mapping of nitrogen and silver on the flake shown in panel (b). f,g) TEM images of GCN/Ag and size distribution of the AgNPs (inset in panel (g)). h) HAADF‐STEM image of GCN/Ag showing the AgNPs as bright spots. i) Light absorption spectra of the starting GCN (bottom green curve), the GCN/Ag+ precursor (middle red curve), and after reduction, the GCN/Ag product (top blue curve).
Figure 2Theoretical models of GCN interacting a) with one silver cation and b) with a silver nanoparticle; 2.21 Å corresponds to the shorter bond. c) XPS survey spectrum of the GCN/Ag. d) Deconvoluted N1s HR‐XPS of the starting GCN and the GCN/Ag product. e) Raman spectra for GCN and GCN/Ag.
Figure 3a) Comparative graph of MIC100 values for GCN/Ag, colloidal silver nanoparticles (AgNPs) and ionic silver (AgNO3) for different bacterial strains. MIC100 values of GCN/Ag refer to the Ag content only, for appropriate comparison with AgNO3 and AgNPs. In Table S2 (Supporting Information), MIC100 values with respect to the total GCN/Ag mass are also available. a)MRSA: methicillin‐resistant S. aureus; b)ESBL: extended‐spectrum β‐lactamases producing Klebsiella pneumoniae. MIC100 values were determined according to the European Committee on Antimicrobial Susceptibility Testing,[ ] as described in the section Methods in the Supporting Information. MIC100 for GCN/Ag with error bars is available in Figure S6 (Supporting Information). b) E. coli treated for several generations (serial passages) at subinhibitory concentrations with the GCN/Ag hybrid (violet) and with colloidal AgNPs (orange). Bacteria developed resistance and inactivated AgNPs, but not GCN/Ag. The serial passages with colloidal AgNPs were performed in the frame of a previous publication[ ] from some of the authors of this work; here these data are plotted for the first time.
Figure 4a) Comparative graph of the antibacterial activity and cytocompatibility of GCN/Ag in healthy human cells compared to representative examples from literature; in the latter case obtained on human cancer cell lines. Extended comparisons are also available in Table S1 (Supporting Information). b) Viability of human lung fibroblasts HEL, human skin fibroblasts BJ, and cancer HeLa cells treated with GCN/Ag, expressed in terms of hybrid (black line) and in terms of silver content (green line) (n = 3. c) Viability of HEL and BJ cells (n = 3) treated with 10 nm AgNPs. d) Leaching test of silver from GCN/Ag in water and in cell‐culture medium after 24, 72 h, and six months. The concentrations on the columns correspond to 0.07%, 0.11%, 0.13%, 0.13%, and 0.14% of Ag leached from the total amount of Ag (200 mg L−1 of Ag) that was initially contained in GCN/Ag which was added in the solution for the leaching test. *p ≤ 0.05; **p ≤ 0.01.
Figure 5Snapshots taken from MD simulation at a) 100 ns and b) 1.0 µs show the interaction of GCN/Ag with the phospholipid membrane. More snapshots are shown in Figures S9 and S10 (Supporting Information) (color coding: cyan and green – carbon; red – oxygen; blue – nitrogen; gray – silver; orange – phosphorus, water molecules, ions, and hydrogen atoms are omitted for clarity); c) SEM image of native E. coli and d,e) treated with GCN/Ag at subinhibitory concentration (0.2 mg mL−1).